Lantern Pharma (LTRN) announced that its Phase 1a trial of LP-184 in advanced solid tumors, including GBM, met all primary endpoints. The study showed a strong safety profile with minimal toxicities and early antitumor activity across tumor types, underscoring the power of Lantern’s AI-driven approach in drug discovery to accelerate oncology development.
